Small molecule therapeutics are the well-established backbone of the pharmaceutical industrys contribution to public health, while monoclonal antibodies and other protein-based therapeutics are the fastest-growing segment of the global drub market.Today, though, the relatively young oligonucleotide therapeutics industry is rapidly approaching an inflection point.Promising signs include an uptick in financial valuations of nucleic acid drug developers, as well as recent technical triumphs overcoming hitherto unresolved drug delivery issues.We can now see dozens of therapeutic oligonucleotide programs advancing through the late phase clinic.This talk will detail the equipment solutions that Asahi Kasei Bioprocess has developed based on its heritage of artisanal fluid management technology designed to unlock efficiencies in clinical and commercial scale oligonucleotide manufacturing.